Literature DB >> 20127058

[EEG-adjusted target-controlled infusion : Propofol target concentration with different doses of remifentanil].

N Büttner1, B Schultz, U Grouven, A Schultz.   

Abstract

BACKGROUND: The aim of this study was to examine to what extent the use of electroencephalography (EEG) monitoring leads to an adaptation of the target-controlled infusion (TCI) concentration of propofol during propofol anaesthesia with different doses of remifentanil. PATIENTS AND METHODS: With ethics committee approval 60 patients (27-69 years old) with American Society of Anesthesiologists classification (ASA) I-III received anaesthestics with propofol (TCI, Diprifusor, AstraZeneca, Wedel, Deutschland) and 0.2, 0.4, or 0.6 microg/kg body weight remifentanil, respectively (groups 1-3). Anaesthesia was maintained at a level of deep hypnosis (EEG stages D(2)/E(0), EEG monitor: Narcotrend, version 2.0/5.0, manufacturer: MT MonitorTechnik, Bad Bramstedt, Germany).
RESULTS: During the steady state the propofol concentration in groups 1-3 was 3.02+/-0.86, 1.93+/-0.53 and 1.60+/-0.55 microg/ml, respectively (p<0.001). Women had a higher propofol consumption than men (p<0.05). Dreams during anaesthesia were more often reported by women than by men (p<0.05). The need for postoperative analgesia decreased with an increasing intraoperative remifentanil dose (p<0.05).
CONCLUSIONS: The study demonstrates that remifentanil has both analgetic and hypnotic effects. With increasing remifentanil dose the propofol requirement decreased and in this context EEG monitoring is useful to adapt the target concentrations of propofol to the patients' age and gender.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20127058     DOI: 10.1007/s00101-009-1666-1

Source DB:  PubMed          Journal:  Anaesthesist        ISSN: 0003-2417            Impact factor:   1.041


  25 in total

1.  [Pain perception: a dynamic process...].

Authors:  W Zieglgänsberger
Journal:  Anaesthesist       Date:  2002-05       Impact factor: 1.041

2.  Dreaming during anaesthesia in adult patients.

Authors:  Kate Leslie; Hannah Skrzypek
Journal:  Best Pract Res Clin Anaesthesiol       Date:  2007-09

Review 3.  [Target-controlled infusion (TCI) - a concept with a future?: state-of-the-art, treatment recommendations and a look into the future].

Authors:  S Schraag; S Kreuer; J Bruhn; C Frenkel; S Albrecht
Journal:  Anaesthesist       Date:  2008-03       Impact factor: 1.041

Review 4.  [Opioids in anesthesia].

Authors:  C Zöllner; M Schäfer
Journal:  Anaesthesist       Date:  2008-07       Impact factor: 1.041

5.  [Incidence and quality of dreaming during anesthesia with propofol in comparison with enflurane].

Authors:  H Käsmacher; M Petermeyer; C Decker
Journal:  Anaesthesist       Date:  1996-02       Impact factor: 1.041

6.  A postanesthetic recovery score.

Authors:  J A Aldrete; D Kroulik
Journal:  Anesth Analg       Date:  1970 Nov-Dec       Impact factor: 5.108

7.  Dreaming during anesthesia and anesthetic depth in elective surgery patients: a prospective cohort study.

Authors:  Kate Leslie; Hannah Skrzypek; Michael J Paech; Irina Kurowski; Tracey Whybrow
Journal:  Anesthesiology       Date:  2007-01       Impact factor: 7.892

8.  Remifentanil dose/electroencephalogram bispectral response during combined propofol/regional anesthesia.

Authors:  Toshiya Koitabashi; Jay W Johansen; Peter S Sebel
Journal:  Anesth Analg       Date:  2002-06       Impact factor: 5.108

9.  [Predictability and precision of "target-controlled infusion" (TCI) of propofol with the "Disoprifusor TCI" system].

Authors:  J Fechner; S Albrecht; H Ihmsen; R Knoll; H Schwilden; J Schüttler
Journal:  Anaesthesist       Date:  1998-08       Impact factor: 1.041

10.  Narcotrend monitoring allows faster emergence and a reduction of drug consumption in propofol-remifentanil anesthesia.

Authors:  Sascha Kreuer; Andreas Biedler; Reinhard Larsen; Simone Altmann; Wolfram Wilhelm
Journal:  Anesthesiology       Date:  2003-07       Impact factor: 7.892

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.